Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules in Type 2 Diabetes (METNODTHYR)
Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study
Sponsor: Centre Hospitalier Universitaire de la Guadeloupe
Listed as NCT04298684, this PHASE4 trial focuses on Diabetes Mellitus, Type 2 and Thyroid Nodule (Benign) and remains ongoing. Sponsored by Centre Hospitalier Universitaire de la Guadeloupe, it has been updated 8 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Mar 2025 — Sep 2025 [monthly]
Unknown PHASE4
-
Sep 2024 — Mar 2025 [monthly]
Unknown PHASE4
-
Aug 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Not Yet Recruiting → Unknown
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE4
▶ Show 3 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Not Yet Recruiting PHASE4
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE4
-
Apr 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Hospitalier Universitaire de la Guadeloupe
For direct contact, visit the study record on ClinicalTrials.gov .